Chlorpromazine v placebo or no treatment in schizophrenia*
| Weighted event rates | ||||
|---|---|---|---|---|
| Outcome | Chlorpromazine | Control | RRR (95%CI) | NNT (CI) |
| *Abbreviations defined in glossary; RRR, RBI, RRI, NNT, NNH, and CI calculated from data in article. | ||||
| Relapse (6 months–2 years) | 40% | 71% | 43% (33 to 52) | 4 (3 to 5) |
| Relapse (2–5 years) | 55% | 83% | 35% (25 to 44) | 4 (3 to 6) |
| Outcome | Chlorpromazine | Control | RBI (95%CI) | NNT (CI) |
| Global improvement (0–8 weeks) | 55% | 37% | 63% (38 to 94) | 6 (5 to 9) |
| Global improvement (9 weeks–6 months) | 30% | 13% | 137% (84 to 207) | 6 (5 to 8) |
| Outcome | Chlorpromazine | Control | RRI (95%CI) | NNH (CI) |
| Sedation | 28% | 13% | 133% (82 to 197) | 7 (6 to 9) |
| Acute movement disorders (dystonia) | 6% | 2% | 214% (30 to 659) | 29 (16 to 131) |
| Parkinsonism | 12% | 7% | 101% (50 to 169) | 21 (14 to 47) |
| Fits | 5% | 2% | 211% (5 to 818) | 30 (20 to 67) |
| Lowered blood pressure | 16% | 8% | 113% (52 to 198) | 13 (9 to 24) |
| Weight gain | 41% | 9% | 351% (118 to 832) | 4 (3 to 6) |
| Photo-sensitivity | 15% | 3% | 504% (222 to 1032) | 9 (7 to 12) |
| Eye opacity or pigment problem | 20% | 7% | 204% (85 to 400) | 8 (6 to 13) |
| Dry mouth | 6% | 1% | 334% (75 to 979) | 21 (14 to 41) |
